Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) is now available.
Sihuan Pharmaceutical has reported that its medical aesthetics and biopharmaceutical businesses form the core of its growth strategy, underpinned by proprietary R&D, a full-spectrum production platform and expanding global reach. The company aims to cement its leadership in China’s medical aesthetics and innovative drug markets through continued commercialization and international expansion.
The group announced that a trustee purchased 3,000,000 shares, or about 0.0328% of its issued share capital, on the market under its share award scheme at an average price of HK$1.3567 per share. Management says this buy supports long-term incentives as Sihuan swings to a 2025 profit of RMB185.4 million on 37.7% revenue growth, driven by a near-doubling of medical aesthetics revenue and accelerating commercialization of innovative drugs, strengthening its growth outlook and alignment with shareholders.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group is an international pharmaceutical and medical aesthetics company listed on the Main Board of the Hong Kong Stock Exchange. It focuses on innovative biopharmaceuticals and medical aesthetics, supported by a leading R&D platform, broad product pipeline, efficient manufacturing and a mature sales network in pursuit of a leading position in China.
Average Trading Volume: 35,639,862
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.53B
Learn more about 0460 stock on TipRanks’ Stock Analysis page.